Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) EBITDA Margin (2018 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed EBITDA Margin for 10 consecutive years, with 34.53% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin fell 496.0% year-over-year to 34.53%, compared with a TTM value of 36.38% through Dec 2025, up 304.0%, and an annual FY2025 reading of 36.38%, up 304.0% over the prior year.
  • EBITDA Margin was 34.53% for Q4 2025 at Catalyst Pharmaceuticals, down from 35.55% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 41.91% in Q4 2022 and bottomed at 29.96% in Q3 2023.
  • Average EBITDA Margin over 5 years is 30.75%, with a median of 34.31% recorded in 2024.
  • The sharpest move saw EBITDA Margin plummeted -11916bps in 2021, then soared 6406bps in 2024.
  • Year by year, EBITDA Margin stood at 24.08% in 2021, then skyrocketed by 74bps to 41.91% in 2022, then decreased by -25bps to 31.51% in 2023, then rose by 25bps to 39.49% in 2024, then decreased by -13bps to 34.53% in 2025.
  • Business Quant data shows EBITDA Margin for CPRX at 34.53% in Q4 2025, 35.55% in Q3 2025, and 35.59% in Q2 2025.